CRNX CRINETICS PHARMACEUTICALS INC Product Launches 8-K Filing 2025 - Positive Study Results Crinetics Pharmaceuticals announced positive results from a Phase 2 study of atumelnant for treating congenital adrenal hyperplasia and plans to present more details in a conference call on January 10, 2025.Get access to all SEC 8-K filings of the CRINETICS PHARMACEUTICALS INC